alexa Gene Therapy: Potential Towards Type- 2 Diabetes Treatment
ISSN: 2155-6156

Journal of Diabetes & Metabolism
Open Access

Like us on:
OMICS International organises 3000+ Global Conferenceseries Events every year across USA, Europe & Asia with support from 1000 more scientific Societies and Publishes 700+ Open Access Journals which contains over 50000 eminent personalities, reputed scientists as editorial board members.

Open Access Journals gaining more Readers and Citations

700 Journals and 15,000,000 Readers Each Journal is getting 25,000+ Readers

This Readership is 10 times more when compared to other Subscription Journals (Source: Google Analytics)

Share This Page

Additional Info

Loading Please wait..

5th World Congress on Diabetes & Metabolism
November 03-05, 2014 Embassy Suites Las Vegas, USA

Vineeta Sharma
ScientificTracks Abstracts: J Diabetes Metab
DOI: 10.4172/2155-6156.S1.026
Type 2 Diabetes (T2D) is an epidemic burden. Number of people suffering from diabetes is increasing at an alarming rate. T2D is one of the most prevalent diseases in developed and under-developed countries. Current therapies for T2D are either direct insulin administration or oral agents that promote insulin secretion. The major drawback of these drugs is frequent clearance from the circulation and hence require daily or frequent intake. Thus, a new treatment that offers a long-term therapeutic effect is sought. One such approach, which might be useful, is gene therapy. AAV based gene therapy expressing insulin, glucagon-like peptide 1 (GLP-1), extendin-4 and leptin are in progress. Among these insulin based gene therapy is complicated as this not only involves insulin generation but also its modification and release. GLP-1 has a short life span in circulation, hence offers only short-term glycemic control. Alternatively, exendin-4, a GLP-1 agonist is an attractive agent as it has longer life span and offers sustained glycemic control up to weeks. Leptin insufficiency in the hypothalamus is the primary pathogenesis of diabetes. Leptin gene therapy has shown tremendous results by controlling blood glucose levels, insulin sensitivity and obesity. We believe that leptin gene therapy holds great potential towards T2D treatment. Although, some obstacles remain to be overcome, gene therapy offers hope for better treatment alternative and possibly a cure for diabetes.
Vineeta Sharma has completed her PhD from All India Institute of Medical Sciences. Dr. Sharma has also completed research internship from the University of Michigan, Ann Arbor and a postdoctoral fellowship from Children?s Hospital Oakland Research Institute. She is the founder and CEO of Adeno Biosciences, a company focusing on developing gene therapy based treatment for obesity and metabolic disorders. She has published 17 scientific papers in reputed journals and is also the recipient of the American Heart Association Fellowship and many other esteemed awards.
image PDF   |   image HTML

Relevant Topics

Peer Reviewed Journals
Make the best use of Scientific Research and information from our 700 + peer reviewed, Open Access Journals
International Conferences 2017-18
Meet Inspiring Speakers and Experts at our 3000+ Global Annual Meetings

Contact Us

© 2008-2017 OMICS International - Open Access Publisher. Best viewed in Mozilla Firefox | Google Chrome | Above IE 7.0 version